Substance / Medication

Irinotecan

Overview

Active Ingredient
irinotecan
RxNorm CUI
51499

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

58 trials linked to this intervention

58
Total Trials
37
Recruiting
9
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients.
Geng Shuai, Shen Yulong, Zhang Chen et al. · Front Pharmacol · 2025
PMID: 40170723Meta-AnalysisFull text (PMC)
Oral probiotic supplementation to alleviate diarrhea induced by fluoropyrimidines or irinotecan-based chemotherapy: A systematic review and meta-analysis.
Siritientong Tippawan, Thet Daylia, Leelakanok Nattawut et al. · Complement Ther Med · 2025
PMID: 39993479Meta-Analysis
Meta-analysis revisiting the influence ofandon irinotecan safety in colorectal cancer patients.
Nguyen Cuc Thi Thu, Nguyen Thi Minh Thuy, Phung Thanh Huong · Pharmacogenomics · 2024
PMID: 39171626Meta-AnalysisFull text (PMC)
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
Merz V, Messina C, Zecchetto C et al. · Clin Oncol (R Coll Radiol) · 2024
PMID: 38129199Meta-Analysis
Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: A systematic review and meta-analysis.
Chen Brian Shiian, Chan Shu-Yen, Bteich Fernand et al. · Crit Rev Oncol Hematol · 2024
PMID: 38735505Meta-Analysis
Treatment of Metastatic Biliary Cancers With Irinotecan and 5-Fluorouracil Based Chemotherapy After Platinum/Gemcitabine Progression: A Systematic Review and Meta-Analysis.
Voutsadakis Ioannis A, Kokkali Stefania, Digklia Antonia · Clin Colorectal Cancer · 2024
PMID: 38902137Meta-Analysis
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Jiang Wei, Liu Qiying, Yang Donglin et al. · Medicine (Baltimore) · 2022
PMID: 36254072Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Irinotecan (substance)
SNOMED CT
372538008
UMLS CUI
C0123931
RxNorm CUI
51499

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
58
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.